If you want to build real wealth in the share market, one of the smartest strategies is to back high-quality ASX growth shares and give them time.
A decade may feel like an eternity in investing terms, but it is long enough for strong businesses to expand, compound earnings, and transform into serious wealth builders.
Right now, the ASX offers no shortage of growth opportunities, but three names that stand out are listed below. Here's why these ASX shares could reward patient investors over the next 10 years:
Goodman Group (ASX: GMG)
Goodman could be one of the most compelling long-term growth stories on the ASX. It has evolved from an industrial property owner into a global infrastructure powerhouse.
Demand for high-quality industrial real estate remains robust, driven by e-commerce and supply-chain optimisation.
In addition, Goodman is increasingly positioned at the heart of the artificial intelligence boom. Its global pipeline includes data-centre-led developments requiring enormous amounts of power and specialised infrastructure, areas where it has both experience and first-mover advantage.
With an exceptional balance sheet, strong development partnerships and a track record of disciplined execution, Goodman is well placed to keep compounding earnings long into the next decade.
Siteminder Ltd (ASX: SDR)
Another ASX growth share that could be a buy for the long term is Siteminder.
Its hotel commerce platform helps accommodation providers manage bookings, pricing, distribution and payment systems from a single cloud-based solution. At the last count, it was generating more than 130 million reservations worth over $85 billion in revenue for its hotel customers each year.
But with many hotels still running outdated legacy systems, the shift toward modern, integrated software represents a long growth runway. In fact, management estimates it has a total addressable market (TAM) of 1 million hotels. This compares to its current customer base of approximately 50,000 properties.
So, with travel markets normalising and hotel operators improving digital investment, Siteminder is positioned for sustained recurring revenue expansion over the next decade.
Telix Pharmaceuticals Ltd (ASX: TLX)
Finally, Telix could be another ASX growth share to buy and hold. This biotech's flagship cancer imaging product, Illuccix, has experienced strong global uptake, underpinning substantial revenue growth and validating the company's radiopharmaceutical platform.
With multiple therapeutic candidates advancing through clinical development, including prostate, kidney, and brain cancer treatments, Telix has the potential to evolve into a major international oncology player.
Especially given how radiopharmaceuticals are emerging as one of the fastest-growing fields in cancer care, offering highly targeted treatment with fewer side effects.
